Merck, Kelun score with sac-TMT in endometrial cancer trial

Merck and Kelun-Biotech reported a phase 3 win for sac-TMT in advanced/recurrent endometrial cancer, with statistically significant improvements in both overall survival and progression-free survival versus chemotherapy in 776 patients. The trial also met its key secondary endpoint of objective response rate, and the companies plan to present the data and discuss regulatory filings globally. The result strengthens sac-TMT's approval prospects beyond China and supports Merck's oncology pipeline as Keytruda faces end-of-decade exclusivity pressure.

Analysis

This is less about one drug readout and more about Merck building a credible post-Keytruda oncology stack before the LOE overhang becomes an earnings event. A first-in-class global phase 3 OS/PFS win in a hard-to-treat, post-platinum/post-IO setting materially de-risks sac-TMT as a platform, and the CNPV compresses the usual FDA timeline enough that U.S. optionality could become a stock catalyst inside 6-12 months rather than a distant pipeline story. The second-order implication is that Merck is no longer just defending share in lung and breast; it is trying to create a repeatable ADC franchise that can support multiple label expansions and combo studies.

Competitive dynamics matter: AZN is the closest public proxy because the broader TROP2 ADC category is turning into a race for sequencing, not just efficacy. If sac-TMT continues to show OS separation across tumor types, it may force competing developers to spend more on trial design and biomarker strategy, raising the bar for differentiation and potentially compressing enthusiasm for later entrants with less robust survival data. The read-through to suppliers is modestly positive for ADC manufacturing/CMC ecosystems, but the bigger market effect is on valuation multiples for oncology platforms with visible late-stage catalysts.

The contrarian risk is that the market may be extrapolating a China-heavy launch pattern into a broad global franchise too early. Regulators outside China will likely scrutinize safety differentiation versus existing ADCs and the durability of OS benefit across subgroups; any ambiguity at ASCO or in filing discussions could delay the pathway by quarters, not weeks. Also, the Keytruda LOE story is still a years-away problem, so the near-term stock reaction may overstate how much this one asset can offset the impending cliff before multiple additional approvals are in hand.

Key Decisions for Investors

• Maintain a tactical long bias in MRK into the ASCO window and first regulatory filing, but use call spreads rather than outright stock to limit downside if broader oncology sentiment fades; 3-6 month horizon, asymmetric upside if U.S./EU filing timing is confirmed.
• Initiate a relative-value long MRK / short AZN pair for 1-3 months if the market starts rewarding late-stage ADC validation broadly; thesis is that MRK has more pipeline re-rating potential from this single asset, while AZN faces more franchise-maturity skepticism.
• Buy MRK Jan-2026 calls or a Jan-2026 call spread to express optionality on sac-TMT becoming a multi-indication asset before Keytruda LOE becomes a valuation problem; risk/reward improves if management signals accelerated filing plans.
• Avoid chasing the move in generic oncology suppliers unless they have direct sac-TMT manufacturing exposure; the catalyst is commercial/regulatory, not a broad capex cycle, so second-order beneficiaries are likely overbought.
• Set a hedge trigger around any ASCO subgroup or safety ambiguity: if OS benefit narrows materially in higher-risk subgroups, expect the market to re-rate the program down over days; use that as an opportunity to reduce long exposure rather than average down.